Target- |
Mechanism- |
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
MH080乳膏在健康受试者及斑块型银屑病患者中的I/Ⅱ期临床试验
[Translation] Phase I/II clinical trial of MH080 cream in healthy subjects and patients with plaque psoriasis
主要目的:评价MH080乳膏在健康受试者中单剂及多剂局部外用给药的安全性和耐受性。
次要目的:评价MH080乳膏在健康受试者中的药代动力学(PK)特征。
[Translation] Primary objective: To evaluate the safety and tolerability of single and multiple topical administration of MH080 cream in healthy subjects.
Secondary objective: To evaluate the pharmacokinetic (PK) characteristics of MH080 cream in healthy subjects.
一项评价含ABI-H2158方案治疗慢性乙型肝炎感染的多中心、单盲、安慰剂对照、多队列的2a期研究
[Translation] A multicenter, single-blind, placebo-controlled, multi-cohort phase 2a study evaluating an ABI-H2158-containing regimen for the treatment of chronic hepatitis B infection
在CHB受试者中评价ABI-H2158 + ETV联合治疗的安全性和耐受性; 在CHB受试者中评价ABI-H2158在降低HBV DNA方面的作用
[Translation] To evaluate the safety and tolerability of ABI-H2158 + ETV combination therapy in CHB subjects; To evaluate the effect of ABI-H2158 in reducing HBV DNA in CHB subjects
Randomized, Open Label, Balanced, Two-Treatment, Two-Period, Two-Sequence, Single Dose, Crossover, Bioequivalence Study of Oseltamivir Phosphate 75 mg Capsule of Yangtze River Pharmaceutical (Group) Co., Ltd., China and TAMIFLU® (Oseltamivir Phosphate) Capsules 75 mg of Genentech, Inc., A Member of the Roche Group, 1 DNA Way, South San Francisco, CA 94080-4990 in Healthy, Adult, Human Subjects Under Fed Condition
This study is to evaluate the bioequivalence of Oseltamivir Phosphate Capsules 75 mg versus TAMIFLU 75 mg capsules administered as 75 mg capsules in healthy volunteers under Fed condition.
100 Clinical Results associated with Austarpharma, Inc.
0 Patents (Medical) associated with Austarpharma, Inc.
100 Deals associated with Austarpharma, Inc.
100 Translational Medicine associated with Austarpharma, Inc.